The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.
The aim of this study is to evaluate the efficacy and safety of the combination of thiotepa and pomalidomide in the treatment of relapsed/refractory (R/R) primary central nervous system lymphoma (PCNSL).
Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
DRUG: thiotepa combined with pomalidomide
Overall Response Rate (ORR), The proportion of subjects who achieves a best overall response of CR or PR., Baseline up to 2 years.|Adverse event rate, The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs)., Baseline up to 3 years.
2-year Progression-free Survival (PFS) rate, The proportion of patients who did not experience disease progression at 2 years., Baseline up to 2 years.|2-year Overall Survival（OS）rate, The proportion of patients who survived at 2 years., Baseline up to 3 years.|Duration of Response（DOR）, From the date that CR or PR are first occurred to the date of objective disease progression or death, whichever occurs first., Baseline up to 2 years.
The aim of this study is to evaluate the efficacy and safety of the combination of thiotepa and pomalidomide in the treatment of relapsed/refractory (R/R) primary central nervous system lymphoma (PCNSL).